Corporate Governance6 Nov 2026, 04:24 pm
Suven Life Sciences: Monitoring Agency Report for Q2 FY27
AI Summary
Suven Life Sciences has submitted its Monitoring Agency (MA) Report for the quarter ended September 30, 2026, issued by CRISIL Ratings Limited. The report pertains to the utilization of proceeds from a Preferential Issue. While there was a deviation from the original objects, it was approved by shareholders at the AGM on August 25, 2026, involving reallocation among existing objects. The deviation range was up to 10%. The preferential issue size was ₹85,764.02 lakhs.
Key Highlights
- Monitoring Agency Report for Q2 FY27 submitted.
- Utilisation of Preferential Issue proceeds reviewed.
- Deviation in objects approved by shareholders.
- Reallocation of funds among existing objects confirmed.
Price Impact
More from SUVEN